YMAB Q1 EPS Forecast Reduced by Brookline Capital Management

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities research analysts at Brookline Capital Management reduced their Q1 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a report issued on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.22) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics' Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.93) EPS.

A number of other research firms have also recently commented on YMAB. Wedbush reissued an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Truist Financial cut their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target for the company. in a research note on Tuesday, April 22nd. Finally, HC Wainwright cut their price target on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.40.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock traded up $0.13 during midday trading on Friday, reaching $4.23. 120,647 shares of the stock were exchanged, compared to its average volume of 327,442. The company's fifty day moving average is $4.82 and its 200-day moving average is $8.03. The firm has a market cap of $191.27 million, a PE ratio of -7.83 and a beta of 0.71. Y-mAbs Therapeutics has a 52 week low of $3.76 and a 52 week high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the company posted ($0.02) EPS.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC lifted its holdings in shares of Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock valued at $119,000 after acquiring an additional 13,890 shares during the last quarter. Wesbanco Bank Inc. purchased a new stake in shares of Y-mAbs Therapeutics in the first quarter worth approximately $244,000. Rhumbline Advisers lifted its stake in shares of Y-mAbs Therapeutics by 4.8% during the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock worth $239,000 after acquiring an additional 2,457 shares during the last quarter. Infinitum Asset Management LLC purchased a new position in Y-mAbs Therapeutics during the 4th quarter valued at $1,218,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Y-mAbs Therapeutics by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock valued at $410,000 after acquiring an additional 7,765 shares during the last quarter. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.